Home Healthcare Biotechnology Viral Vaccines Market

Viral Vaccines Market Size, Share & Trends Analysis Report By Types (Live attenuated vaccines, Inactivated vaccines, Sub-Unit viral vaccines), By Consumer groups (Pediatric, Adults), By Disease Indication (Cancer, Influenza, Human Papilloma Virus, Rota Virus, Poliomyelitis, Hepatitis, Others), By Route of Administration (Parenteral, Oral) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: July 24, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Viral Vaccines Market, By Types 2022-2034 (USD MILLION/ Units)
    1. Live attenuated vaccines
    2. Inactivated vaccines
    3. Sub-Unit viral vaccines
  2. Viral Vaccines Market, By Consumer groups 2022-2034 (USD MILLION/ Units)
    1. Pediatric
    2. Adults
  3. Viral Vaccines Market, By Disease Indication 2022-2034 (USD MILLION/ Units)
    1. Cancer
    2. Influenza
    3. Human Papilloma Virus
    4. Rota Virus
    5. Poliomyelitis
    6. Hepatitis
    7. Others
  4. Viral Vaccines Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Parenteral
    2. Oral
  5. Regional Viral Vaccines Market
    1. North America
      1. North America Viral Vaccines Market By Types 2022-2034 (USD MILLION/ Units)
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
      2. North America Viral Vaccines Market By Consumer groups 2022-2034 (USD MILLION/ Units)
        1. Pediatric
        2. Adults
      3. North America Viral Vaccines Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Cancer
        2. Influenza
        3. Human Papilloma Virus
        4. Rota Virus
        5. Poliomyelitis
        6. Hepatitis
        7. Others
      4. North America Viral Vaccines Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
      5. U.S.
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      6. Canada
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
    2. Europe
      1. Europe Viral Vaccines Market By Types 2022-2034 (USD MILLION/ Units)
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
      2. Europe Viral Vaccines Market By Consumer groups 2022-2034 (USD MILLION/ Units)
        1. Pediatric
        2. Adults
      3. Europe Viral Vaccines Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Cancer
        2. Influenza
        3. Human Papilloma Virus
        4. Rota Virus
        5. Poliomyelitis
        6. Hepatitis
        7. Others
      4. Europe Viral Vaccines Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
      5. U.K.
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      6. Germany
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      7. France
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      8. Spain
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      9. Italy
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      10. Russia
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      11. Nordic
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      12. Benelux
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      13. Rest of Europe
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
    3. APAC
      1. APAC Viral Vaccines Market By Types 2022-2034 (USD MILLION/ Units)
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
      2. APAC Viral Vaccines Market By Consumer groups 2022-2034 (USD MILLION/ Units)
        1. Pediatric
        2. Adults
      3. APAC Viral Vaccines Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Cancer
        2. Influenza
        3. Human Papilloma Virus
        4. Rota Virus
        5. Poliomyelitis
        6. Hepatitis
        7. Others
      4. APAC Viral Vaccines Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
      5. China
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      6. Korea
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      7. Japan
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      8. India
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      9. Australia
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      10. Singapore
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      11. Taiwan
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      12. South East Asia
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      13. Rest of Asia-Pacific
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
    4. Middle East and Africa
      1. Middle East and Africa Viral Vaccines Market By Types 2022-2034 (USD MILLION/ Units)
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
      2. Middle East and Africa Viral Vaccines Market By Consumer groups 2022-2034 (USD MILLION/ Units)
        1. Pediatric
        2. Adults
      3. Middle East and Africa Viral Vaccines Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Cancer
        2. Influenza
        3. Human Papilloma Virus
        4. Rota Virus
        5. Poliomyelitis
        6. Hepatitis
        7. Others
      4. Middle East and Africa Viral Vaccines Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
      5. UAE
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      6. Turkey
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      7. Saudi Arabia
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      8. South Africa
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      9. Egypt
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      10. Nigeria
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      11. Rest of MEA
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
    5. LATAM
      1. LATAM Viral Vaccines Market By Types 2022-2034 (USD MILLION/ Units)
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
      2. LATAM Viral Vaccines Market By Consumer groups 2022-2034 (USD MILLION/ Units)
        1. Pediatric
        2. Adults
      3. LATAM Viral Vaccines Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Cancer
        2. Influenza
        3. Human Papilloma Virus
        4. Rota Virus
        5. Poliomyelitis
        6. Hepatitis
        7. Others
      4. LATAM Viral Vaccines Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
      5. Brazil
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      6. Mexico
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      7. Argentina
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      8. Chile
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      9. Colombia
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
      10. Rest of LATAM
        1. Live attenuated vaccines
        2. Inactivated vaccines
        3. Sub-Unit viral vaccines
        4. Pediatric
        5. Adults
        6. Cancer
        7. Influenza
        8. Human Papilloma Virus
        9. Rota Virus
        10. Poliomyelitis
        11. Hepatitis
        12. Others
        13. Parenteral
        14. Oral
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.